Genital Neoplasms, Female
Information
- Disease name
- Genital Neoplasms, Female
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05051696 | Active, not recruiting | Phase 2 | Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies | September 26, 2021 | March 30, 2025 |
| NCT00190983 | Completed | Phase 2 | A Trial for Patients With Advanced/Recurrent Cervical Cancer | February 2005 | October 2007 |
| NCT00191607 | Completed | Phase 3 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | July 2002 | November 2005 |
| NCT00191646 | Completed | Phase 3 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | October 2002 | August 2009 |
| NCT00377520 | Completed | Phase 2 | A Trial for Patients With Advanced/Recurrent Endometrial Cancer | September 2006 | September 2008 |
| NCT00121030 | Completed | Phase 2 | Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy | October 2002 | December 2003 |
| NCT00523432 | Completed | Phase 1 | A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies | August 2007 | December 2010 |
| NCT01074697 | Completed | Phase 3 | Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin | April 2010 | April 2015 |
| NCT01654458 | Completed | N/A | A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer | July 2012 | September 2019 |
| NCT02182245 | Completed | Phase 1 | Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies | October 2005 | |
| NCT02609880 | Completed | N/A | Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer | July 2009 | May 2, 2023 |
| NCT02966327 | Completed | N/A | Effect of Early Compression and Exercise on Lymphedema Incidence in Patients With Gynecological Cancer | June 1, 2015 | October 31, 2019 |
| NCT04679675 | Completed | N/A | Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial | November 20, 2020 | July 29, 2023 |
| NCT04807166 | Not yet recruiting | Phase 2 | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer | June 1, 2021 | December 1, 2024 |
| NCT05360459 | Recruiting | Characterization of the Intestinal and Vaginal Microbiota in Long-term Survivors of Gynecological Cancer | May 20, 2022 | May 2025 | |
| NCT04519151 | Recruiting | Phase 2 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | April 12, 2021 | November 2029 |
| NCT02499952 | Terminated | Phase 2 | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors | January 2016 | January 13, 2017 |
| NCT00332280 | Terminated | Phase 2/Phase 3 | Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo | May 2006 | March 2010 |
| NCT01032447 | Terminated | Overcoming Obstacles to Clinical Trials Enrollment Through a Navigator Program | January 2010 | July 2013 | |
| NCT04556071 | Unknown status | Phase 2 | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | November 6, 2020 | October 1, 2022 |
| NCT04566952 | Unknown status | Phase 2 | Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer | October 28, 2020 | October 1, 2023 |
| NCT00391664 | Unknown status | Questionnaire Study for Gynecological Cancer Survivors | February 2006 | February 2011 | |
| NCT02781155 | Unknown status | Phase 1/Phase 2 | Limiting Chemotherapy Side Effects by Using Moxa | February 2016 | September 2017 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D005833